🔎 Trials Near Me

Utama › Kanser Paru-paru Sel Kecil › Missouri › St. Louis

Kajian klinikal Kanser Paru-paru Sel Kecil di St. Louis, MO

13 kajian untuk Kanser Paru-paru Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar St. Louis (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

Mengambil pesertaFasa 3
  • Mercy South, St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT07218146

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Mengambil pesertaFasa 3
  • Washington University School of Medicine, St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT06712355

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • WA Uni School Of Med, St Louis
Umur 18 hingga 100 · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT06726148

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Mengambil pesertaFasa 1
  • Washington University Medicine, St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT07488923

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Mengambil pesertaFasa 1/2
  • Washington University School of Medicine, St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT07155200

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Mengambil pesertaFasa 3
  • Mercy Clinic Oncology and Hematology Sindelar Cancer Center, St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06203210

DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

Mengambil pesertaFasa 1
  • Washington University School of Medicine, St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT07545954

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Mengambil pesertaFasa 1/2
  • Washington University School of Medicine (Siteman Cancer Center), St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT05652686

A Study of LY4175408 in Participants With Advanced Cancer

Mengambil pesertaFasa 1
  • Washington University, St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jun 2026 · NCT07046923

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Mengambil pesertaFasa 2
  • Siteman Cancer Center, Washington University, St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Mei 2026 · NCT05363280

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Mengambil pesertaFasa 2
  • Mercy Hospital South, St Louis
  • Mercy Hospital Saint Louis, St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Mac 2026 · NCT06769126

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • Washington University, St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Feb 2026 · NCT07030257

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • Washington University, St Louis
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Jan 2026 · NCT05490472

Kajian Kanser Paru-paru Sel Kecil di bandar lain

Kajian lain di St. Louis

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.